BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1983324)

  • 1. Maintenance therapy of duodenal ulcer with H2-receptor antagonists--a meta-analysis.
    Palmer RH; Frank WO; Karlstadt R
    Aliment Pharmacol Ther; 1990 Jun; 4(3):283-94. PubMed ID: 1983324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inhibition of 24-hour acidity by nizatidine].
    Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
    Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical review of histamine2 receptor antagonists.
    Lipsy RJ; Fennerty B; Fagan TC
    Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
    Poynard T; Lemaire M; Agostini H
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.
    Gledhill T; Howard OM; Buck M; Paul A; Hunt RH
    Gut; 1983 Oct; 24(10):904-8. PubMed ID: 6311692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G
    Digestion; 1985; 32 Suppl 1():62-9. PubMed ID: 2866137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
    Freston JW
    Am J Gastroenterol; 1987 Dec; 82(12):1242-9. PubMed ID: 2891294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morning versus evening dose: a comparison of three H2-receptor blockers in duodenal ulcer healing.
    Khasawneh SM; Affarah HB
    Am J Gastroenterol; 1992 Sep; 87(9):1180-2. PubMed ID: 1519576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe.
    Simon B; Cremer M; Dammann HG; Hentschel E; Keohane PP; Mulder H; Müller P; Sarles H
    Scand J Gastroenterol Suppl; 1987; 136():61-70. PubMed ID: 2892257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs.
    Savarino V
    Ital J Gastroenterol; 1990; 22 Suppl 2():20-3. PubMed ID: 1983412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of twice-daily ranitidine with standard cimetidine treatment of duodenal ulcer.
    Walt RP; Trotman IF; Frost R; Golding PL; Shepherd TH; Rawlings J; Hunt RH; Colin-Jones D; Milton-Thompson GJ; Misiewicz JJ
    Gut; 1981 Apr; 22(4):319-22. PubMed ID: 6113192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T; Hirata W; Higichi S
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 24-hour acid suppression profile of nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Müller P; Simon B; Keohane P
    Scand J Gastroenterol Suppl; 1987; 136():56-60. PubMed ID: 2892256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
    Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
    Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
    Nwokolo CU; Smith JT; Gavey C; Sawyerr A; Pounder RE
    Aliment Pharmacol Ther; 1990; 4 Suppl 1():29-45. PubMed ID: 1983345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ranitidine and cimetidine ulcer maintenance therapy.
    Kurata JH; Koch GG; Nogawa AN
    J Clin Gastroenterol; 1987 Dec; 9(6):644-50. PubMed ID: 3327884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H2-receptor antagonists: development and application.
    Feldman S
    N Engl Reg Allergy Proc; 1986; 7(4):362-6. PubMed ID: 2886903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to "H2-receptor antagonists and duodenal ulcer recurrence".
    Kurata JH; Nogawa AN; Koch GG
    Am J Gastroenterol; 1988 Dec; 83(12):1427-9. PubMed ID: 2904219
    [No Abstract]   [Full Text] [Related]  

  • 20. Determining the optimal dosage regimen for H2-receptor antagonist therapy--a dose validation approach.
    Young MD; Frank WO; Dickson BD; Peace KP; Braverman A; Mounce W
    Aliment Pharmacol Ther; 1989 Feb; 3(1):47-57. PubMed ID: 2577482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.